Under the terms of the agreement, Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million
The objective of this Phase 1 is to determine safety, bio-distribution, and preliminary effectiveness of AlphaMedix in patients with somatostatin receptor positive neuroendocrine tumors (NETs). Orano Med’s CEO
The Phase II trial (BGBC007) follows a two-stage design: it is an open label, multi-centre study of bemcentinib in combination with KEYTRUDA in patients with previously treated, locally
As a result of the Acquisition, DanDrit owns a perpetual, fully paid up, royalty free, sublicensable, exclusive, license to new technology platforms for the treatment of HIV, including
As announced in a press release dated November 7, 2017, a previous U.S Phase III study did not meet its primary endpoint – change in worst leg pain
QVAR® RediHaler™ is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and
NF1 is an incurable genetic condition that affects one in 3,000 births, with highly-variable symptoms, including cutaneous (skin), neurological (nervous system) and orthopaedic (skeletal) manifestations. NF1 can cause
Fluarix Tetra has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two
The proceeds from the commitment will be used to refinance Veloxis's outstanding debt, accelerate the growth of Envarsus XR in the US and help fund working capital of
The transaction adds the Universal Donor Cell technology to Astellas Pharma with which it will create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.